68 reports of this reaction
2.5% of all ARGATROBAN reports
#9 most reported adverse reaction
THROMBOCYTOPENIA is the #9 most commonly reported adverse reaction for ARGATROBAN, manufactured by Accord Healthcare Inc.. There are 68 FDA adverse event reports linking ARGATROBAN to THROMBOCYTOPENIA. This represents approximately 2.5% of all 2,692 adverse event reports for this drug.
Patients taking ARGATROBAN who experience thrombocytopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THROMBOCYTOPENIA is a less commonly reported adverse event for ARGATROBAN, but still significant enough to appear in the safety profile.
In addition to thrombocytopenia, the following adverse reactions have been reported for ARGATROBAN:
The following drugs have also been linked to thrombocytopenia in FDA adverse event reports:
THROMBOCYTOPENIA has been reported as an adverse event in 68 FDA reports for ARGATROBAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
THROMBOCYTOPENIA accounts for approximately 2.5% of all adverse event reports for ARGATROBAN, making it a notable side effect.
If you experience thrombocytopenia while taking ARGATROBAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.